Menu Search
Equities

Aurobindo Pharma Ltd

AUROPHARMA:NSI

Aurobindo Pharma Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)1,223.70
  • Today's Change6.70 / 0.55%
  • Shares traded494.22k
  • 1 Year change+16.05%
  • Beta0.9466
Data delayed at least 15 minutes, as of Nov 22 2024 10:19 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy7
Outperform11
Hold4
Sell2
Strong Sell2

Share price forecast in INR

The 26 analysts offering 12 month price targets for Aurobindo Pharma Ltd have a median target of 1,537.50, with a high estimate of 1,930.00 and a low estimate of 1,225.00. The median estimate represents a 26.34% increase from the last price of 1,217.00.
High58.6%1,930.00
Med26.3%1,537.50
Low0.7%1,225.00

Dividends

In 2024, Aurobindo Pharma Ltd reported a dividend of 4.50 INR, which represents a 50.00% increase over last year. The 19 analysts covering the company expect dividends of 4.87 INR for the upcoming fiscal year, an increase of 8.22%.
Div growth (TTM)50.00%
More ▼

Earnings history & estimates in INR

On Nov 09, 2024, Aurobindo Pharma Ltd reported 2nd quarter 2025 earnings of 14.00 per share.
The next earnings announcement is expected on Feb 08, 2025.
Average growth rate+3.28%
Aurobindo Pharma Ltd reported annual 2024 earnings of 57.43 per share on May 25, 2024.
Average growth rate+10.58%
More ▼

Revenue history & estimates in INR

Aurobindo Pharma Limited had 2nd quarter 2025 revenues of 77.96bn. This bettered the 77.50bn consensus of the 14 analysts covering the company. This was 13.80% above the prior year's 2nd quarter results.
Average growth rate+1.95%
Aurobindo Pharma Limited had revenues for the full year 2024 of 290.02bn. This was 16.68% above the prior year's results.
Average growth rate+6.15%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.